{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreihpg2yefnk5cltbb7lpbkqlmg5e763fo5qas3q7xicyxvkywo3k4q",
    "uri": "at://did:plc:7ltlvigjik37fxbx2bat4p22/app.bsky.feed.post/3moy7dt6k5ua2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreicxp4mwikmftkvabn3dmp6pwdrvgsy75ml65jeog6auj5d3wqjmcq"
    },
    "mimeType": "image/jpeg",
    "size": 83555
  },
  "path": "/mental-health/single-dose-lsd-depression-trial/",
  "publishedAt": "2026-06-23T17:39:27.000Z",
  "site": "https://refractor.io",
  "tags": [
    "Continue Reading",
    "Mental Health",
    "Brain Health",
    "Body and Mind",
    "Psychedelic Medicine",
    "mental health",
    "Depression",
    "Anxiety",
    "PTSD",
    "clinical trials",
    "FDA"
  ],
  "textContent": "Definium Therapeutics has announced strong results in a phase 3 trial of its single-dosed lysergide (LSD) drug DT120 in treating adults with major depressive disorder (MDD), meeting its primary goal and all key secondary efficacy endpoints in the first trial of its kind.\n\nContinue Reading\n\n**Category:** Mental Health, Brain Health, Body and Mind\n\n**Tags:** Psychedelic Medicine, mental health, Depression, Anxiety, PTSD, clinical trials, FDA",
  "title": "Single-dose LSD drug successfully treats depression in key human trial"
}